Home  »  Hot Stocks   »  Is Phathom Pharmaceuticals Inc. (PHAT) a Keeper?...

Is Phathom Pharmaceuticals Inc. (PHAT) a Keeper?

Phathom Pharmaceuticals Inc. (NASDAQ:PHAT) went down by -5.56% from its latest closing price compared to the recent 1-year high of $36.09. The company’s stock price has collected 0.50% of gains in the last five trading sessions.

Is It Worth Investing in Phathom Pharmaceuticals Inc. (NASDAQ :PHAT) Right Now?

Opinions of the stock are interesting as 3 analysts out of 4 who provided ratings for Phathom Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 0 as “sell.”

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


The average price from analysts is $33.50, which is $29.58 above the current price. PHAT currently public float of 29.57M and currently shorts hold a 19.46% ratio of that float. Today, the average trading volume of PHAT was 260.31K shares.

PHAT’s Market Performance

PHAT stocks went up by 0.50% for the week, with a monthly jump of 11.33% and a quarterly performance of 22.94%, while its annual performance rate touched -68.57%. The volatility ratio for the week stands at 9.54% while the volatility levels for the past 30 days are set at 9.25% for Phathom Pharmaceuticals Inc. The simple moving average for the period of the last 20 days is 7.90% for PHAT stocks with a simple moving average of -21.16% for the last 200 days.

Analysts’ Opinion of PHAT

Goldman, on the other hand, stated in their research note that they expect to see PHAT reach a price target of $48, previously predicting the price at $40. The rating they have provided for PHAT stocks is “Neutral” according to the report published on May 12th, 2021.

BMO Capital Markets gave a rating of “Outperform” to PHAT, setting the target price at $63 in the report published on February 17th of the previous year.

PHAT Trading at 6.50% from the 50-Day Moving Average

After a stumble in the market that brought PHAT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -72.24% of loss for the given period.

Volatility was left at 9.25%, however, over the last 30 days, the volatility rate increased by 9.54%, as shares surge +7.63% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +3.51% upper at present.

During the last 5 trading sessions, PHAT rose by +0.50%, which changed the moving average for the period of 200-days by -46.50% in comparison to the 20-day moving average, which settled at $9.32. In addition, Phathom Pharmaceuticals Inc. saw -49.06% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at PHAT starting from Nabulsi Azmi, who purchase 20,000 shares at the price of $8.16 back on May 16. After this action, Nabulsi Azmi now owns 785,700 shares of Phathom Pharmaceuticals Inc., valued at $163,288 using the latest closing price.

Curran Terrie, the President and Chief Executive of Phathom Pharmaceuticals Inc., purchase 20,500 shares at $7.41 during a trade that took place back on May 13, which means that Curran Terrie is holding 64,595 shares at $151,835 based on the most recent closing price.

Stock Fundamentals for PHAT

Equity return is now at value -317.60, with -84.10 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 9.86.

Is Cadence Bank (CADE) a Keeper?

Cadence Bank (NYSE:CADE) went down by -0.52% from its latest closing price compared to the recent 1-year high of $34.24. The company’s stock price has